(Reuters) – Transition Therapeutics Inc said an early-stage study of its experimental type 2 diabetes drug showed significant improvement in blood sugar control and reductions in body weight, sending its shares up more than 65 percent.
A once-weekly administered dose of the drug, codenamed TT-401, showed an acceptable safety and tolerability profile for all doses.
The drug was tested in five doses on diabetic patients and in one dose on non-diabetic obese patients, the company said.
s of Transition Therapeutics, whose other products include a treatment for Alzheimer’s disease, touched a high of C$3.72 on Tuesday on the Toronto Stock Exchange.
The company’s Nasdaq-listed stock was trading up 49 percent at $3.35.
(Reporting by Bhaswati Mukhopadhyay in Bangalore; Editing by Roshni Menon)
